Advanced in Febrile Neutropenia

Dr. Emma L. Barber

Oncology
250 E Superior St Ste 4-420, Prentice Women's Hospital, 
Chicago, IL 
Clinical Trials:Currently Recruiting for 1 Trial
Offers Telehealth
20 Years of Experience
Advanced in Febrile Neutropenia
250 E Superior St Ste 4-420, Prentice Women's Hospital, 
Chicago, IL 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Emma Barber is an Oncologist in Chicago, Illinois. Dr. Barber has been practicing medicine for over 20 years and is rated as an Advanced provider by MediFind in the treatment of Febrile Neutropenia. Her top areas of expertise are Endometrial Cancer, Ovarian Cancer, Ovarian Carcinosarcoma, Vulvectomy, and Endoscopy.

Her clinical research consists of co-authoring 93 peer reviewed articles and participating in 7 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, she has co-authored 1 article in the study of Febrile Neutropenia.

Graduate Institution
Yale University School Of Medicine, 2006.0
Residency
McGaw Medical Center of Northwestern University
Specialties
Oncology
Licenses
Obstetrics & Gynecology in IL
Board Certifications
American Board Of Obstetrics And Gynecology - Gynecologic Oncology (Certified)
Fellowships
University of North Carolina Hospitals
Hospital Affiliations
Northwestern Memorial Hospital
Northwestern Lake Forest Hospital
Palos Community Hospital
Northwestern Medicine Delnor Community Hospital
Northwestern Medicine Central Dupage Hospital
Languages Spoken
English
Gender
Female

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem
  • EPO
  • HMO
  • POS
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Meridian Choice
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 5 Less Insurance Carriers -

Locations

250 E Superior St Ste 4-420, Prentice Women's Hospital, Chicago, IL 60611

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

7 Clinical Trials

A Phase 1/1b Dose Escalation Study of Abemaciclib and Olaparib for Recurrent Platinum-Resistant Ovarian Cancer
A Phase 1/1b Dose Escalation Study of Abemaciclib and Olaparib for Recurrent Platinum-Resistant Ovarian Cancer
Enrollment Status: Recruiting
Publish Date: December 17, 2025
Intervention Type: Drug, Procedure
Study Drug: Abemaciclib
Study Phase: Phase 1
Surgical Window of Opportunity Study of Megestrol Acetate Compared With Megestrol Acetate and Metformin for Endometrial Intraepithelial Neoplasia
Surgical Window of Opportunity Study of Megestrol Acetate Compared With Megestrol Acetate and Metformin for Endometrial Intraepithelial Neoplasia
Enrollment Status: Active_not_recruiting
Publish Date: December 02, 2025
Intervention Type: Other, Procedure, Drug
Study Drugs: Extended Release Metformin Hydrochloride, Megestrol Acetate
Study Phase: Phase 2
A Phase III Randomized Trial of Radiation +/- Pembrolizumab (MK-3475) for Newly Diagnosed Early Stage High Intermediate Risk Mismatch Repair Deficient (dMMR) Endometrioid Endometrial Cancer
A Phase III Randomized Trial of Radiation +/- Pembrolizumab (MK-3475) for Newly Diagnosed Early Stage High Intermediate Risk Mismatch Repair Deficient (dMMR) Endometrioid Endometrial Cancer
Enrollment Status: Active_not_recruiting
Publish Date: November 12, 2025
Intervention Type: Other, Procedure, Radiation, Biological
Study Drug: Pembrolizumab
Study Phase: Phase 3
A Pilot, Multicenter, Single Arm, Open Label, Surgical Window of Opportunity Study of Abemaciclib and Letrozole for Endometrioid Adenocarcinoma of the Endometrium
A Pilot, Multicenter, Single Arm, Open Label, Surgical Window of Opportunity Study of Abemaciclib and Letrozole for Endometrioid Adenocarcinoma of the Endometrium
Enrollment Status: Completed
Publish Date: October 17, 2025
Intervention Type: Drug, Procedure
Study Drugs: Abemaciclib, Letrozole
Study Phase: Early Phase 1
A Randomized Phase III, Two-Arm Trial of Paclitaxel/Carboplatin/Maintenance Letrozole Versus Letrozole Monotherapy in Patients With Stage II-IV, Primary Low-Grade Serous Carcinoma of the Ovary or Peritoneum
A Randomized Phase III, Two-Arm Trial of Paclitaxel/Carboplatin/Maintenance Letrozole Versus Letrozole Monotherapy in Patients With Stage II-IV, Primary Low-Grade Serous Carcinoma of the Ovary or Peritoneum
Enrollment Status: Active_not_recruiting
Publish Date: October 08, 2025
Intervention Type: Drug, Procedure
Study Drugs: Carboplatin, Letrozole, Paclitaxel
Study Phase: Phase 3
A Pilot Study of Prehabilitation During the Neoadjuvant Window of Opportunity in Older Women With Ovarian Cancer (FIT4SURGERY)
A Pilot Study of Prehabilitation During the Neoadjuvant Window of Opportunity in Older Women With Ovarian Cancer (FIT4SURGERY)
Enrollment Status: Completed
Publish Date: April 29, 2025
Intervention Type: Behavioral
Study Phase: Not Applicable
An Open Label Phase II Trial of Guadecitabine and Pembrolizumab in Platinum Resistant Recurrent Ovarian Cancer
An Open Label Phase II Trial of Guadecitabine and Pembrolizumab in Platinum Resistant Recurrent Ovarian Cancer
Enrollment Status: Completed
Publish Date: February 20, 2024
Intervention Type: Drug, Other, Biological
Study Drugs: Guadecitabine, Pembrolizumab
Study Phase: Phase 2
View 6 Less Clinical Trials

93 Total Publications

Health Care Disparities in Gynecologic Oncology.
Health Care Disparities in Gynecologic Oncology.
Journal: Hematology/oncology clinics of North America
Published: October 31, 2025
Similar Doctors
Shira N. Dinner
Distinguished in Febrile Neutropenia
Dr. Shira N. Dinner
Hematology | Oncology
Distinguished in Febrile Neutropenia
Dr. Shira N. Dinner
Hematology | Oncology
675 N St Clair St Ste 21-100, Galter Pavilion, 
Chicago, IL 
 (0.1 miles away)
866-587-4322
Experience:
19+ years
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Shira Dinner is a Hematologist and an Oncologist in Chicago, Illinois. Dr. Dinner has been practicing medicine for over 19 years and is rated as a Distinguished provider by MediFind in the treatment of Febrile Neutropenia. Her top areas of expertise are Acute Myeloid Leukemia (AML), Acute Lymphoblastic Leukemia (ALL), Febrile Neutropenia, Bone Marrow Aspiration, and Bone Marrow Transplant.

Advanced in Febrile Neutropenia
Dr. Steven A. Sandler
Oncology | Hematology
Advanced in Febrile Neutropenia
Dr. Steven A. Sandler
Oncology | Hematology

Cook County

500 E 51st St, 
Chicago, IL 
 (6.4 miles away)
312-572-2000
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Steven Sandler is an Oncologist and a Hematologist in Chicago, Illinois. Dr. Sandler is rated as a Distinguished provider by MediFind in the treatment of Febrile Neutropenia. His top areas of expertise are Thrombocytopenia, Colorectal Cancer, Familial Colorectal Cancer, Chronic Familial Neutropenia, and Bone Marrow Aspiration. Dr. Sandler is currently accepting new patients.

Distinguished in Febrile Neutropenia
Dr. Patrick A. Hagen
Hematology Oncology | Hematology | Oncology
Distinguished in Febrile Neutropenia
Dr. Patrick A. Hagen
Hematology Oncology | Hematology | Oncology

Loyola University Medical Center

2160 S 1st Ave, 
Maywood, IL 
 (11.6 miles away)
708-216-9000
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Patrick Hagen is a Hematologist Oncology specialist and a Hematologist in Maywood, Illinois. Dr. Hagen is rated as a Distinguished provider by MediFind in the treatment of Febrile Neutropenia. His top areas of expertise are Multiple Myeloma, Acute Myeloid Leukemia (AML), Hodgkin Lymphoma, Bone Marrow Transplant, and Bone Marrow Aspiration. Dr. Hagen is currently accepting new patients.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Barber's expertise for a condition
ConditionClose
View All 14 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile